# West Pharmaceutical Services (WST) Financial Model Free Excel 3-statement financial model and company analysis for West Pharmaceutical Services. - Canonical: https://finamodel.com/companies/west-pharmaceutical-services - Industry: Medical Devices - Downloadable model: Yes - Excel download: https://finamodel.com/company-models/WST.xlsx ## Model Purpose This model provides a comprehensive equity valuation and scenario analysis framework to determine the intrinsic value of West Pharmaceutical Services (WST) based on its exposure to high-value product (HVP) components, biologics growth, and GLP-1 auto-injector adoption. ## Company Overview West Pharmaceutical Services is a leading global manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The company designs and produces elastomer-based components, seals, and auto-injector systems that are critical to the safe and effective delivery of biologics, vaccines, and small-molecule drugs. Business segments include: * Proprietary Products (approximately 80% to 82% of total revenue) * Contract-Manufactured Products (approximately 18% to 20% of total revenue) Key geographies are split with approximately 55% of revenue generated from international markets and 45% from the United States. The business model is asset-heavy due to precision manufacturing requirements, but it benefits from highly recurring revenue because its components are typically specified directly into a customer's regulatory filings (such as FDA approvals), creating massive switching costs. West holds a dominant competitive position and market share in elastomer packaging, competing primarily with Stevanato Group, Gerresheimer, and AptarGroup. Recent major events include a period of customer inventory destocking in 2023 and 2024, followed by a return to strong organic growth in 2025 driven by the rapid adoption of GLP-1 weight-loss drugs and new Annex 1 regulatory standards requiring higher-quality packaging. ## Revenue Deep Dive ### Proprietary Products * **Segment name:** Proprietary Products * **Revenue driver formula:** Injectable Drug Volume x Blended Average Selling Price (driven by mix shift to High-Value Products) * **Historical growth rate:** 4% to 8% organic CAGR, with recent quarters accelerating to high-single digits. * **Key growth levers and headwinds:** Growth is heavily driven by the transition from standard packaging to High-Value Products (HVP) like NovaPure, FluroTec, and Westar, which command significant price premiums. The explosion of GLP-1 receptor agonists and biologics requires advanced self-injection device platforms. Headwinds include periodic customer inventory destocking and generic drug volume declines. * **Pricing dynamics:** Contractual with high pricing power. Because the cost of the packaging is a fraction of the final drug price but critical to safety, customers are relatively price-insensitive. * **Revenue recognition notes:** Recognised primarily at a point in time when control of the products transfers to the customer (typically upon shipment). * **Seasonality:** Relatively balanced across the year, though Q4 often sees a slight uptick due to year-end pharmaceutical purchasing cycles. ### Contract-Manufactured Products * **Segment name:** Contract-Manufactured Products * **Revenue driver formula:** Number of Active Manufacturing Contracts x Average Revenue per Contract * **Historical growth rate:** 1% to 3% organic CAGR. * **Key growth levers and headwinds:** Driven by demand for self-injection devices for obesity and diabetes, offset by declines in legacy healthcare diagnostic devices. * **Pricing dynamics:** Cost-plus or fixed-price contracts. Margins are significantly lower than the Proprietary segment because West does not own the underlying intellectual property of the devices. * **Revenue recognition notes:** Recognised over time or at a point in time depending on whether the manufactured product has an alternative use and if West has an enforceable right to payment for performance completed to date. * **Seasonality:** Minimal seasonality; driven by specific customer product launch timelines. ## Cost Structure ### Variable Costs / COGS * COGS includes raw materials (synthetic elastomers, plastics, aluminium), direct manufacturing labour, facility overhead, and depreciation of manufacturing equipment. * Consolidated gross margin has historically ranged from 36% to 39%. * Key input costs include petroleum-based raw materials and energy costs. * COGS scales with a degree of operating leverage. As the mix shifts toward HVP, gross margins expand because the incremental cost to produce a coated or washed stopper (HVP) is far lower than the price premium charged. ### Operating Expenses * **R&D:** Typically runs at 1.5% to 2.0% of revenue. It covers the development of new elastomer formulations, containment solutions, and advanced auto-injector mechanisms. * **SG&A:** Typically 11% to 13% of revenue. This includes sales, marketing, and general administrative headcount, as well as enterprise IT investments. * **Depreciation & Amortisation:** Embedded primarily in COGS (for manufacturing PP&E) and SG&A. * **Stock-Based Compensation:** Runs at approximately 1.0% to 1.5% of revenue. * **Restructuring / one-time charges:** Infrequent, though occasional facility consolidation costs or temporary disruption costs (such as the 2025 Arizona facility disruption) occur. ### Margin Profile * Gross margin: 36% to 39%. Proprietary Products operate at 40% to 43% gross margin, while Contract-Manufactured Products operate at 12% to 17% gross margin. * Operating margin: 21% to 23%. * Net margin: 16% to 18%. * Margins are generally expanding over the long term due to the mix shift toward HVP, which carries structurally higher profitability. ## Balance Sheet Structure * Total assets are approximately $3.5 billion to $4.0 billion. * Key asset categories are Property, Plant, and Equipment (PP&E) and Inventory. PP&E is the largest line item due to the capital-intensive nature of precision manufacturing and cleanroom facilities. * Goodwill & intangibles represent a small portion of total assets (typically under 10%), as West relies primarily on organic growth rather than transformational M&A. * Working capital profile: * Days Sales Outstanding (DSO): 45 to 55 days. * Days Inventory Outstanding (DIO): 70 to 90 days. High inventory is required to ensure zero stockouts for critical pharmaceutical customers. * Days Payable Outstanding (DPO): 35 to 45 days. * Net working capital is positive and consumes cash during periods of high growth. * PP&E consists of global manufacturing facilities, cleanrooms, and specialised moulding equipment. Useful lives range from 10 to 40 years for buildings and 3 to 15 years for machinery. * Right-of-use assets are present but not a dominant feature of the balance sheet compared to owned manufacturing sites. ## Capital Expenditure & Investment * Capex as a percentage of revenue typically ranges from 8% to 12%. In FY2025, capex was $285.9 million (approximately 9.3% of revenue). * Growth capex represents the majority of recent spend, specifically targeted at expanding HVP manufacturing capacity and commercial drug handling operations (such as the Dublin facility). * Capitalised software costs are minimal compared to physical plant investments. * M&A pattern is strictly bolt-on. The company occasionally acquires small technology firms or buys out joint venture partners (such as increasing ownership in Daikyo), but organic growth is the primary engine. ## Debt & Capital Structure * Total debt is very low, typically under $300 million, resulting in a net cash position or near-zero net debt. * Debt/EBITDA ratio is consistently below 0.5x. * Key debt instruments include a revolving credit facility and senior unsecured notes. * Interest rate profile is highly manageable given the low debt balances, with interest income on cash often offsetting interest expense. * The share repurchase programme is highly active. West repurchased $560 million in stock in 2024 and $134 million in 2025. * Dividend policy features a low payout ratio (typically under 15%) and a low yield (under 0.5%), but the company has a long history of consistent annual dividend increases. ## Cash Flow Characteristics * Operating cash flow conversion is excellent, with OCF routinely exceeding Net Income (OCF was $754.8 million in FY2025). * Free cash flow margin typically ranges from 10% to 15% (FCF was $468.9 million in FY2025). * Major non-cash items bridging net income to OCF include depreciation, amortisation, and stock-based compensation. * Working capital is a use of cash during expansion phases, particularly as inventory builds are required to support new HVP product launches. * Capex intensity is currently elevated to support GLP-1 and biologics demand but is expected to normalise slightly as major facility build-outs complete. * The effective tax rate typically ranges from 17% to 19%, benefiting from stock-based compensation tax benefits and foreign earnings mix. ## Sheet Structure 1. **Assumptions**: Contains all hardcoded inputs for macroeconomic drivers, segment growth rates, margin profiles, working capital days, capex percentages, and WACC. 2. **Revenue & Gross Margin**: Builds revenue and COGS from the bottom up for the two reported segments (Proprietary Products and Contract-Manufactured Products). 3. **Income Statement**: Consolidated view linking revenue and gross profit from the segment sheet, subtracting SG&A, R&D, and interest to arrive at Net Income and EPS. 4. **Balance Sheet**: Standard presentation of Assets, Liabilities, and Shareholders' Equity. Must balance in all periods. 5. **Cash Flow Statement**: Indirect method starting with Net Income, adjusting for non-cash items, changes in working capital, capex, debt issuance/repayment, and shareholder returns. 6. **Working Capital & Capex**: Schedules for accounts receivable, inventory, accounts payable, and a PP&E rollforward (beginning balance plus capex minus depreciation). 7. **Debt Schedule**: Tracks revolver and term debt balances, calculating interest expense based on average balances and interest income on cash. 8. **DCF Valuation**: Calculates Unlevered Free Cash Flow, applies the discount rate, calculates the terminal value, and bridges enterprise value to equity value per share. ## Key Financial Relationships 1. Proprietary Products Revenue = Prior Year Proprietary Revenue * (1 + Proprietary Organic Growth Rate) 2. Contract-Manufactured Revenue = Prior Year CM Revenue * (1 + CM Organic Growth Rate) 3. Consolidated Net Sales = Proprietary Products Revenue + Contract-Manufactured Revenue 4. Proprietary COGS = Proprietary Products Revenue * (1 - Proprietary Gross Margin %) 5. Contract-Manufactured COGS = Contract-Manufactured Revenue * (1 - Contract-Manufactured Gross Margin %) 6. Consolidated Gross Profit = Proprietary Revenue - Proprietary COGS + Contract-Manufactured Revenue - Contract-Manufactured COGS 7. SG&A Expense = Consolidated Net Sales * SG&A % of Revenue 8. R&D Expense = Consolidated Net Sales * R&D % of Revenue 9. Operating Profit = Consolidated Gross Profit - SG&A Expense - R&D Expense 10. Accounts Receivable = (Consolidated Net Sales / 365) * DSO 11. Inventory = (Consolidated COGS / 365) * DIO 12. Accounts Payable = (Consolidated COGS / 365) * DPO 13. Free Cash Flow = Cash from Operations - Capital Expenditures 14. Ending Shares Outstanding = Beginning Shares Outstanding - (Share Repurchase Amount / Average Share Price) ## Cross-Sheet Dependencies * The **Assumptions** sheet feeds all other sheets. No hardcodes should exist outside this sheet. * The **Revenue & Gross Margin** sheet calculates the top-line and direct costs, feeding directly into the **Income Statement**. * The **Income Statement** generates Net Income, which is the starting point for the **Cash Flow Statement** and feeds Retained Earnings on the **Balance Sheet**. * The **Working Capital & Capex** sheet calculates changes in NWC and depreciation, which feed the **Cash Flow Statement** and the **Balance Sheet** (PP&E and working capital line items). * The **Debt Schedule** uses cash flow deficits/surpluses from the **Cash Flow Statement** to draw down or pay down the revolver, and feeds Interest Expense back to the **Income Statement**. This creates a circular reference that requires a toggle switch to break. * The **DCF Valuation** pulls NOPAT and D&A from the **Income Statement**, Capex and NWC changes from the **Cash Flow Statement**, and current net debt from the **Balance Sheet**. ## Sign Convention * Revenues, asset balances, liability balances, and equity balances are entered and displayed as positive numbers. * On the Income Statement, expenses (COGS, SG&A, R&D, Interest, Taxes) are calculated as positive numbers and subtracted to reach profit subtotals. * On the Cash Flow Statement, cash inflows are positive and cash outflows (such as Capex, dividends, share repurchases, and working capital increases) are negative. ## Things Most Likely to Go Wrong * Applying a consolidated gross margin assumption instead of modelling the segments separately. The Proprietary segment has a gross margin near 42%, while Contract Manufacturing is near 15%. A mix shift changes the consolidated margin significantly. * Failing to account for the massive impact of High-Value Products (HVP). HVP drives both top-line growth and gross margin expansion; the model must reflect margin expansion if Proprietary growth outpaces Contract Manufacturing. * Underestimating capital expenditures. West is in a heavy investment cycle to build capacity for GLP-1 and biologics packaging. Capex should remain elevated in the near term before normalising. * Overcomplicating the debt schedule. West operates with very little debt; the focus of the model should be on cash generation and share repurchases rather than complex leverage metrics. * Ignoring foreign exchange impacts. With 55% of sales outside the US, currency fluctuations can swing reported revenue. The model should assume constant currency for future projections. * Miscalculating inventory days. West must hold significant inventory to serve pharma clients; modelling a drastic reduction in DIO will artificially inflate projected free cash flow. * Double-counting depreciation. Ensure D&A is properly allocated between COGS and operating expenses so that EBITDA reconciles correctly. * Forgetting the share count reduction. West uses its substantial free cash flow to buy back stock consistently, which provides a steady tailwind to EPS. ## Validation Checks * Consolidated Gross Margin should remain between 36% and 40%. Flag if it falls outside this band. * Proprietary Products should represent 80% to 85% of total revenue. * Capex as a percentage of revenue should run between 8% and 11%. * Operating cash flow must exceed Net Income in every projected year. * The Balance Sheet must balance exactly: Total Assets minus (Total Liabilities + Shareholders' Equity) must equal zero. * Effective tax rate should remain between 17% and 19%. * Debt/EBITDA should remain below 1.0x given the company's conservative balance sheet. * Free Cash Flow margin should be between 12% and 18%. ## Key Assumptions (Default Values) | Assumption | Default Value | Unit | Rationale | |---|---|---|---| | Proprietary Products Revenue Growth | 6.5 | % | Reflects strong underlying demand for HVP and GLP-1 components, normalising after 2024 destocking. | | Contract-Manufactured Revenue Growth | 2.5 | % | Historical average for this lower-growth, mature segment. | | Proprietary Products Gross Margin | 41.5 | % | Based on recent historical averages and continued HVP mix shift. | | Contract-Manufactured Gross Margin | 15.0 | % | Based on recent historical averages for the contract business. | | SG&A as % of Revenue | 12.0 | % | Consistent with management guidance and historical run rates. | | R&D as % of Revenue | 1.8 | % | Historical average required to maintain product innovation. | | Days Sales Outstanding (DSO) | 50 | Days | Calculated from recent balance sheet receivables and revenue. | | Days Inventory Outstanding (DIO) | 80 | Days | Calculated from recent balance sheet inventory and COGS. | | Days Payable Outstanding (DPO) | 40 | Days | Calculated from recent balance sheet payables and COGS. | | Capex as % of Revenue | 9.0 | % | Aligns with FY2025 actuals and FY2026 management guidance ($250M-$275M). | | Effective Tax Rate | 18.0 | % | Historical average effective tax rate. | | Annual Share Repurchases | 150 | $ Millions | Conservative estimate based on recent historical buyback activity. | | Dividend Payout Ratio | 12.0 | % | Reflects the company's policy of steady, small dividend increases. | | Cost of Debt | 4.5 | % | Estimated weighted average interest rate on current debt facilities. | | WACC | 7.5 | % | Appropriate discount rate for a low-beta, highly stable healthcare supplier. | | Terminal Growth Rate | 3.0 | % | Reflects long-term GDP growth plus a premium for the structural growth in biologics. | ## Data Sources & Benchmarks * **Filings:** SEC EDGAR for West Pharmaceutical Services (WST) 10-K and 10-Q filings. The Investor Relations page on westpharma.com provides earnings presentations and transcript data. * **Peers for Benchmarking:** Stevanato Group (STVN), Gerresheimer AG (GXI.DE), AptarGroup (ATR), and Catalent (CTLT). * **Industry Data:** IQVIA reports on global medicine spending and biologics pipelines; FDA approval databases for new injectable drugs. * **Consensus Estimates:** FactSet or Bloomberg for forward-looking revenue and EPS consensus to validate model outputs against street expectations. ## Sources * West Pharmaceutical Services FY2025 10-K and Q4 2025 Earnings Release (February 2026). * West Pharmaceutical Services FY2024 10-K and Q4 2024 Earnings Release (February 2025). * West Pharmaceutical Services Q1 2025 Earnings Release (April 2025). * Seeking Alpha Earnings Call Transcripts for WST. * PitchBook company profile and financial summary for West Pharmaceutical Services. --- ## Frequently asked questions ### What does West Pharmaceutical Services (WST) do? West Pharmaceutical Services is a leading global manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The company designs and produces elastomer-based components, seals, and auto-injector systems essential for the safe and effective delivery of various pharmaceutical products. ### What are the primary revenue drivers for West Pharmaceutical Services? West Pharmaceutical Services' revenue is primarily driven by its exposure to high-value product (HVP) components, the growth in biologics, and the adoption of GLP-1 auto-injectors. The business benefits from highly recurring revenue because its components are typically specified directly into customer regulatory filings, creating significant switching costs. ### What is the typical capital expenditure as a percentage of revenue for West Pharmaceutical Services? Capital expenditure for West Pharmaceutical Services typically ranges from 8% to 12% of revenue, reflecting its asset-heavy business model due to precision manufacturing requirements. For example, in FY2025, capex was approximately 9.3% of revenue, with a significant portion allocated to expanding HVP manufacturing capacity. ### What are the key profitability assumptions used in the financial model for West Pharmaceutical Services? The financial model for West Pharmaceutical Services assumes a Cost of Goods Sold (COGS) as a percentage of revenue at approximately 62.43%. Additionally, Selling, General, and Administrative (SGA) expenses are modeled at about 12.93% of revenue, contributing to the company's overall profitability profile. ### What is the forecast horizon for the West Pharmaceutical Services financial model used for valuation? The financial model for West Pharmaceutical Services provides a comprehensive equity valuation and scenario analysis based on a forecast horizon from fiscal year 2026 through fiscal year 2030. This allows for a detailed assessment of the company's intrinsic value over a multi-year period. ### Is there a downloadable financial model available for West Pharmaceutical Services (WST)? Yes, a downloadable Excel financial model is available for West Pharmaceutical Services (WST). This general corporate model offers a framework for equity valuation and scenario analysis, incorporating key assumptions about the company's financials and business drivers. [Interactive forecast calculator](https://finamodel.com/companies/west-pharmaceutical-services/forecast)